RxDoctor Payments Data

Garth Vaz, MD

Family Medicine · Gonzales, TXNPI 1285636647

Payments from drug & device makers

$194,296in general payments, 2019–2025

Across 152 payments — averaging $1278.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$79K
  • Amgen$47K
  • Astrazeneca UK Limited$31K
  • Novo Nordisk AS$22K
  • AstraZeneca$9K
  • Gilead$5K
  • plus $323 from 7 others
$1,138in research payments, 2019–2025

Across 15 payments — averaging $75.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$1K

What the payments were for

  • Food & beverage$354100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$194,296 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$170,144
Medicare patients
149
Services billed
29,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$102,354
FarxigaDapagliflozin Propanediol47$40,792
EliquisApixaban36$35,943
JanuviaSitagliptin Phosphate14$21,025
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$18,578
VascepaIcosapent Ethyl28$17,954
JardianceEmpagliflozin13$16,898
Combivent RespimatIpratropium/Albuterol Sulfate21$15,445
TradjentaLinagliptin13$13,573
EntrestoSacubitril/Valsartan12$12,780
LinzessLinaclotide19$10,403
SymbicortBudesonide/Formoterol Fumarate33$8,866
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,814
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,729
Pantoprazole Sodium169$6,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$39$102,35481 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$9,484$58,38892 claims
PfizerEliquis$15$35,94336 claims
AbbVieLinzess$118$10,40319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Gonzales

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →